My guess is that SelectVaccines would have been none the wiser in relation to this decision by Genelabs. However, it does explain why there was no action happening, and it is very disappointing. The fact that they have decided to sell diagnostics gives an indication of their view of SLT's Hep E kit. They obviously did not see enough value in it to warrant keeping the diagnostics unit. Unfortunately this appears to be the view of most investors as well.
It will be interesting to see what happens from here, I think the initial reaction will be a dump in some shares. Obviously all is not lost as you say, as maybe actin will finally be taken to finalise a deal, and there is of course the Hep C and A. High-risk stock, certainly, with all the eggs in the one basket, its a make or break proposition, and it'll be decided within the next 6-9 months I think.
Cheers
SLT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
